Upgrade to SI Premium - Free Trial

Alzamend Neuro (ALZN)

1.22 -0.03 (2.40%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (12/12/25 *Est.)

Latest Headlines

Form 8-K Alzamend Neuro, Inc. For: Apr 17 April 17, 2026 4:31 PM - SEC Filing Form 4 Alzamend Neuro, Inc. For: Apr 14 Filed by: AULT MILTON C III April 16, 2026 4:30 PM - SEC Filing Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital April 7, 2026 12:37 PM - PR NewsWire Alzamend Neuro reports early brain study data for AL001 compound April 7, 2026 8:07 AM - StreetInsider Alzamend Neuro reports AL001 meets bioequivalence in phase II trial March 26, 2026 8:02 AM - StreetInsider Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All March 26, 2026 8:01 AM - PR NewsWire Full Article List